Lilly's retatrutide shows sweeping obesity and cardiometabolic benefits in Phase 3 trials
Lilly revealed that retatrutide, a once‑weekly GIP/GLP‑1/glucagon triple agonist, produced major weight loss (up to 70.3 lbs, 28.3% at 80 weeks) and strong A1C reductions (up to 2.0%) in Phase 3 TRIUMPH-1 and TRANSCEND-T2D-1, plus meaningful knee osteoarthritis pain and sleep apnea improvements, suggesting potential to treat obesity and its related complications; results were presented at the ADA 86th Scientific Sessions and published in The Lancet.